Literature DB >> 23094537

Analysis of idiopathic ventricular tachycardia in childhood.

Esra Kiliç1, Alpay Celiker, Tevfik Karagöz, Dursun Alehan, Süheyla Ozkutlu, Sema Ozer.   

Abstract

Idiopathic ventricular tachycardia (VT) is a relatively benign and rare form of VT. It is seen in young people without demonstrable cardiac pathology. The aim of our study was to review the clinical picture of idiopathic VT, before evaluating the indications for antiarrhythmic treatment and the efficacy of radiofrequency ablation (RFA). The notes of patients diagnosed with idiopathic VT in the last 13 years (n: 22) were included in the study. The median age of onset was 11 years (1 month-16 years). We evaluated the findings regarding the diagnosis, treatment and prognosis of these patients. The most common initial symptom was palpitation, in 15 cases. Five children with idiopathic VT were symptom-free. VT was of right ventricular origin in 10 patients and left ventricular origin in 8 patients. Beta-blockers were the mainstay of medical treatment in right VT and calcium channel blockers (Ca-channel blocker) were mostly used in left VT cases. The success rate of RFA was 57% in right VT and 100% in left VT. The median follow-up was 41 months (9 months-60 months), and all patients are alive currently with no symptoms. VT without demonstrable cardiac pathology is associated with a good prognosis. Treatment is unnecessary for asymptomatic non-sustained VT. RFA is useful in patients with symptomatic drug-refractory idiopathic VT arising from the left or right ventricle.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23094537

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  1 in total

1.  Clinical spectrum and long-term course of sustained ventricular tachycardia in pediatric patients: 10 years of experience.

Authors:  Fatma Sevinç Şengül; Hasan Candaş Kafalı; Alper Güzeltaş; Yakup Ergül
Journal:  Anatol J Cardiol       Date:  2021-05       Impact factor: 1.596

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.